338992-42-0

Basic information

• Product Name: N-7-benzyloxy-(4-chloro-2,6-difluorophenyl)-6-methoxy-4-quinazilinylamine
• Synonyms: N-7-benzyloxy-(4-chloro-2,6-difluorophenyl)-6-methoxy-4-quinazilinylamine
• CAS NO: 338992-42-0
• Molecular Weight: 427.838
• Mol File: 338992-42-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-7-benzyloxy-(4-chloro-2,6-difluorophenyl)-6-methoxy-4-quinazilinylamine(CAS DataBase Reference)
• NIST Chemistry Reference: N-7-benzyloxy-(4-chloro-2,6-difluorophenyl)-6-methoxy-4-quinazilinylamine(338992-42-0)
• EPA Substance Registry System: N-7-benzyloxy-(4-chloro-2,6-difluorophenyl)-6-methoxy-4-quinazilinylamine(338992-42-0)

Safety Data

• Hazardous Substances Data: 338992-42-0(Hazardous Substances Data)

Upstream product

• 162364-72-9 7-benzyloxy-4-chloro-6-methoxyquinazoline 
• 69411-06-9 2,6-difluoro-4-chloroaniline 

Downstream Products

• 338992-46-4 tert-butyl 4-[({4-[(4-chloro-2,6-difluorophenyl)amino]-6-methoxyquinazolin-7-yl}oxy)methyl]piperidine-1-carboxylate 
• 338992-44-2 N-(4-chloro-2,6-difluorophenyl)-7-hydroxy-6-methoxy-4-quinazolinylamine 

Relevant articles and documents

QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS

The invention relates to quinazoline derivatives of the formula I:- wherein: m is an integer from 1 to 3; R 1 represents halogeno or C 1-3 alkyl; X 1 represents -O-; R 2 is selected from one of the following three groups: 1) C 1-5 alkylR 3 (wherein R 3 is piperidin-4-yl which may bear one or two substituents selected from hydroxy, halogeno, C 1-4 alkyl, C 1-4 hydroxyalkyl and C 1-4 alkoxy; 2) C 2-5 alkenylR 3 (wherein R 3 is as defined hereinbefore); 3) C 2-5 alkynylR 3 (wherein R 3 is as defined hereinbefore); and wherein any alkyl, alkenyl or alkynyl group may bear one or more substituents selected from hydroxy, halogeno and amino; and salts thereof; processes for their preparation, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.